Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CNTX 
Context Therapeutics Inc (CNTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: CNTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -5.76% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.57M USD | Price to earnings Ratio - | 1Y Target Price 5.75 |
Price to earnings Ratio - | 1Y Target Price 5.75 | ||
Volume (30-day avg) 287253 | Beta 1.86 | 52 Weeks Range 0.49 - 2.75 | Updated Date 06/18/2025 |
52 Weeks Range 0.49 - 2.75 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.01% | Return on Equity (TTM) -55.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -38592267 | Price to Sales(TTM) - |
Enterprise Value -38592267 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.6 | Shares Outstanding 89704200 | Shares Floating 39385523 |
Shares Outstanding 89704200 | Shares Floating 39385523 | ||
Percent Insiders 2.33 | Percent Institutions 79.93 |
Analyst Ratings
Rating 4.4 | Target Price 5.75 | Buy 3 | Strong Buy 2 |
Buy 3 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Context Therapeutics Inc
Company Overview
History and Background
Context Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for hormone-driven cancers. Founded to address unmet needs in women's oncology, the company has evolved through preclinical and clinical development stages. Specific founding year and earlier detailed milestones require accessing proprietary information.
Core Business Areas
- Apremilast Development: Development of onapristone extended release (ONA-XR), an oral progesterone receptor (PR) antagonist, for the treatment of PR+ cancers. Focus is on clinical trials for various cancer types.
Leadership and Structure
Details on leadership and specific structure would require access to non-public organizational charts. The company is led by its CEO and has a management team overseeing clinical development, research, and business operations.
Top Products and Market Share
Key Offerings
- Onapristone Extended Release (ONA-XR): ONA-XR is the lead product candidate, an oral progesterone receptor (PR) antagonist in Phase 2 clinical trials. Market share is currently 0, as it is still in development. Potential competitors include existing hormonal therapies and emerging PR antagonists.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically in oncology, is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market is driven by unmet medical needs and advancements in targeted therapies.
Positioning
Context Therapeutics is positioned as a company focused on hormone-driven cancers, particularly through its progesterone receptor antagonist ONA-XR. Its competitive advantage lies in its novel approach targeting PR+ cancers.
Total Addressable Market (TAM)
The TAM for hormone-driven cancers is significant, estimated in the billions of dollars annually. Context Therapeutics' positioning within this TAM is targeted towards specific PR+ cancer subtypes with unmet needs, representing a subset of the overall market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting progesterone receptor
- Lead product candidate in clinical trials
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
- Single lead product candidate creates concentration risk
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through additional indications or therapeutic candidates
Threats
- Clinical trial failures
- Competition from established therapies and emerging competitors
- Regulatory hurdles and delays
- Changes in the healthcare landscape and reimbursement policies
Competitors and Market Share
Key Competitors
- ARRY
- PFE
- AZN
Competitive Landscape
Context Therapeutics faces competition from established pharmaceutical companies and other biotechnology firms developing therapies for hormone-driven cancers. Its competitive advantage lies in its targeted approach to progesterone receptor antagonism.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily measured by progress in clinical development rather than revenue generation.
Future Projections: Future growth is dependent on successful clinical trials and potential regulatory approvals. Analyst estimates would be needed for specific projections.
Recent Initiatives: Recent initiatives include advancing clinical trials for ONA-XR and exploring potential partnerships.
Summary
Context Therapeutics is a development-stage company focused on hormone-driven cancers, particularly through its lead candidate ONA-XR. Its success hinges on positive clinical trial outcomes. The company's limited financial resources and dependence on a single product candidate pose significant risks, but successful development could lead to substantial market opportunities. Close monitoring of trial results and strategic partnerships are crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. The analysis is based on publicly available information and may not be exhaustive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Context Therapeutics Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2021-10-20 | Co-Founder, President, CEO & Director Mr. Martin A. Lehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | |
Full time employees 12 | |||
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.